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Abstract
There is increased awareness of transgender physical and mental health widely and in academic 
research. A significant proportion of transgender men will retain their cervix with an increased 
risk of cervical cancer. In this review of cervical cancer screening among transgender men, we try 
to estimate how many transgender men still have a cervix, understand to identify challenges and 
barriers to cervical screening and propose possible solutions. Organised cervical screening 
programmes need to consider the needs of this population, in particular the provison of HPV self-
sampling. 
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Tweetable Abstract
Transgender men need access to cervical screening
Background 
As transgender people face increasing acceptance in society, transgender physical and mental 
health is receiving growing interest in academic research. Both WHO and the American 
Psychiatric Association recently removed transgender identity from the list of psychiatric 
disorders1. There remains many uncertainties and challenges to be resolved for the appropriate 
care and management of transgender people in the health care system.
Gender-affirming care maybe easier to access as  the recognition of patient’s rights, informed 
consent and self-determination start to dismantle barriers such as gate-keeping and 
marginalisation and indeed ignorance. Transgender people should now be able to dictate their 
own  transition path based on their personal needs and preferences2. Some may choose to have 
gender-affirming hormone therapy and access sequential surgical procedures as well as change 
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The transgender population offer a diversity of health needs, linked either to their gender 
identity, to their assigned gender at birth or both. This can be a complex challenge to healthcare 
systems when it comes to programs based on sex-specific health needs, such as cervical, breast 
or prostate cancer screening. 
In this paper on cervical screening among transgender men (TM, “individuals who were assigned 
the female gender at birth, but identify as male or along a transmasculine spectrum”3), we will 
try to estimate the risk of cervical cancer in this population, understand how it affects them, try 
to identify problems and propose tentative solutions.
Legal transition refers to the administrative change of the name and/or the legal gender. Medical 
transition can encompass androgen therapy and/or one or several surgical procedures. The most 
common surgical procedures among TM patients are, in descending order, bilateral mastectomy, 
hysterectomy (with or without removal of the ovaries) and genital reassignment surgery4,5
Prevalence of transgenderism
Depending on the chosen definition, estimates on prevalence can vary substantially. Researchers 
have been using different proxies such as the number of people identifying with another gender 
than the one assigned at birth, attending a gender clinic, starting gender-affirming hormone 
therapy, requesting or having for surgery or legally changing one’s gender6. A recent review of 
prevalence estimated that self-identified transgender and gender non-conforming individuals 
represented 100 to 2,000 per 100,000 of the global population (0.1% to 2%), and that 1 to 30 per 
100,000 individuals would receive gender-affirming care7. 
The ratio of transgender women (TW) to transgender men is generally above 1, but has varied 
widely over time and it is now getting closer to 12. In Goodman’s review7, estimates for TM 
ranged from 200 to 7,300 per 100,000 for individuals self-identifying as transgender ; from 0.7 to 
420 per 100,000 for those who received a diagnosis of Gender Identity Disorder or similar, and 
from 0.25 to 12 per 100,000 for those who actually received transgender-affirming care. The 
Netherlands was one of the few countries which provided prevalence estimates for these three 
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The gap between people self-identifying as transgender and those accessing gender-affirming 
care can be explained by several factors. First, not all transgender people want to undergo 
gender-affirming treatment or, indeed, have the resources to do so. Secondly, the data included 
in the review were collected between 1960 and 2015, and access to gender-affirming care has 
considerably changed over this periond2. Thirdly , while self-identification can be assessed in 
nation-wide surveys, access to care was measured in clinic-based studies; a selected part of the 
population7. And lastly, even for trans people who are willing to access gender-affirming services, 
the diagnostic criteria of the DSM-V and the ICD-10 require that the gender dysphoria has to be 
persistent for a certain period – generally 2 years – before being allowed to access gender-
affirming care8.  These all contribute to a considerable proportion of TM retaining their cervix.
How many transgender men have a cervix?
In the 2015 U.S Transgender Survey (USTS), 71% of TM (n=7,950) ever received androgen therapy 
and 14% had hysterectomy5. Similarly, in the biggest Dutch clinic for gender-affirming care, 
72.9% of adult TM (n=1,624) had started androgen therapy and 83.8% of those who were on 
testosterone for more than 1.5 years had undergone oophorectomy2.
It appears that a substantial proportion of TM have a cervix, even though 57% of TM in the USTS 
indicated that they wanted to have a hysterectomy ultimately. Permanent sterilisation (defined 
as the definitive loss of the reproductive function) used to be listed as a mandatory step to 
change one’s legal gender, and as a recent Lancet’s editorial highlighted, it is still the case in 
many places such as Japan or some US states1. Growing acceptance of transgender people in 
society is leading to less restrictive laws5. In 2012, Sweden became the first country to abolish 
the requirement for hysterectomy/oophorectomy for legal change of gender followed by 26 
other countries in Europe9.  
While some experts argue for hysterectomy/oophorectomy, and point to the additional 
preventive advantage that transmen after surgical removal may not develop cervical cancer and 
have a much reduced risk of ovarian cancer, others including healthcare professionals (HCPs) 
point to the individual’s autonomy suggesting that regular screening according to the guidelines 
for cisgender women (whose gender identity matches the sex that they were assigned at birth) 









This article is protected by copyright. All rights reserved
This will lead to two things. First, as legal and medical arguments for hysterectomy weaken, we 
can expect a growing population of transgender men who retain their cervix and so, their need 
for cervical screening. Second, while some TMs with a cervix will remain registered legally as 
women, an increasing proportion will be registered as men. In Belgium, for example, 40% 
(n=605) of all legal gender changes among TM occurred in the year following removal of 
sterilization from the legal list of requirements13. In the context of a population-based preventive 
programme, those TMs could be missed from call-recall as the process to identify the target 
population uses data on current  legal gender status.
Are transgender men with a cervix exposed to HPV and cervical cancer ?
Persistent infection with high-risk types of HPV is a true prerequisite for cervical intra-epithelial 
neoplasia (CIN). With regular screening,  and the treatment of high-grade CIN, the development 
of invasive cancer can be avoided14. We found only one study estimating HPV prevalence in TM 
(mean age 27.5y, SD 5.7), showing 16% of high-risk HPV positivity in self-collected vaginal swabs, 
a prevalence which is comparable to cisgender women15. TMs could even be at greater risk of 
HPV infection than cisgender women: there is some evidence that TM individuals engage in 
sexual activity with partners across the gender spectrum, have multiple concurrent partners, 
engage in condomless receptive vaginal and/or anal sex with cisgender men and have higher 
rates of STI diagnoses, despite low rates of screening16. According to the USTS5 self-reported HIV 
prevalence was 0.3% among TM compared with <0.1% for the general US population17. No data 
exist on the risk of cervical cancer in TM, but an increased risk compared with the general 
population could be anticipated given the higher rates of STIs. 
The prevalence of HPV and uptake of cervical cancer screening among TM could be assessed 
from screening and cancer registries if transgender status is collected. Retrieving data from such 
epidemiological studies would be possible with appropriate ethical, information governance and 
research approvals and provide a useful insight for service providers. 
According to a WHO-report TM who retain their female genitalia often miss out on cervical 
screening and other sexual health services, as they may not seek out or may not be included in 
the target lists for screening invitations based on the gender recorded in population registries. As 
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prevalence, TMs are particularly at risk of cervical cancer due to a lower uptake of screening3,19 
compared with cisgender women. In the USTS, 27% of TM who still had their cervix had a Pap 
test in the last year against 43% of the adult cisgender female population in the US5. In another 
US-study3, 64.3% of TM were up to date with screening recommendation against 73.5% of 
cisgender women. Additionally, TM have more inadequate Pap test results due to 
cytomorphological changes (atrophy) associated with androgen therapy20,21.  The androgenic 
effect on genital tract, with tissue epithelial atrophy and tissue shrinkage, results in speculum 
insertion and cervical screening test collection being more uncomfortable and indeed painful.
What are the barriers that transgender men face in assessing cervical cancer screening?
Systemic barriers stemming from the health care system can apply to general access to care for 
transgender people, while other barriers are specific to access to cervical cancer prevention for 
TM. The intrapersonal barriers are tied to TM individuals’ knowledge, behavior and practice, 
while the structural barriers are from external causes. Table 1 shows the different barriers TMs 
are faced with. Still TMs are often faced with discrimination and stigmatization by HCP’s, leading 
to a delay in treatment16. Moreover, in many countries there is a lack of insurance coverage for 
gender-affirming surgical procedures. Specifically, on cervical cancer screening, barriers include 
the lack of TM-targeted education material and the absence of specific guidelines16,23. Important 
intrapersonal barriers include a high prevalence of past sexual and/or emotional trauma, the 
distress associated with genital examination and the general distrust of healthcare delivery 
systems3,16,19,24.
Table 1. Structural, intrapersonal, systemic and specific barriers to cervical cancer screening for 
TM.
Recommendations for screening programs and healthcare professionals
Training of HCPs is essential to improve transgender access to health care in general as well as 
cervical screening and HPV vaccination. Training HCPA needs to include care of transgender 
patients22. Intervention research shows that training on LGBT+ (Lesbian, Gay, Bisexual and 
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topics as short as half-day for fifth-year undergraduate students improved their confidence to 
clinically assess a transgender patient from 35% to 84%25. Cytologists need to be aware of the 
particular features of dysplasia in atrophic cervical cells, in order to avoid over- and under-
diagnosis21. 
If atrophy is clearly present vaginal application of estriol or estradiol (cream, gel or tablets) 
during one or two months before taking the pap-smear should be considered. Due to vaginal 
atrophy, and possibility of no previous penetrative sex, the speculum exam should be performed 
by an appropriately trained or experienced HCP’s and with the smallest possible speculum or 
replaced by a HPV test. 
Self- or provider-collected HPV NAAT (nucleic acid amplification testing) can be a solution in this 
population by reducing physical and psychological discomfort and fear associated with this 
medical procedure19. Accuracy of HPV testing on self- vs provider-collected HPV testing is similar 
for detection of CIN in cisgender women when using clinically-validated PCR-based HPV DNA 
assay26,27. However, Reisner et al. found that HPV testing in self-collected vaginal specimens was 
less sensitive than in provider-collected cervical specimens  (71.4%) among TM15. Ninety percent 
of TM participants expressed a preference for self- over provider-collection. Some had concerns 
and suggested developing new tools to facilitate self-sampling technique and empower them to 
use these and so support a subset of the population who would otherwise not undergo screening 
15. In the general female population, the offer of self-sampling devices is more effective than 
invitation or reminder letters to reach non-screened women27 .
Organized cervical screening programs should not overlook transgender men. A specific opt-in 
procedure should be foreseen to allow inclusion in the target population for cervical cancer 
screening for TM with a cervix. This includes TM who have not undergone hysterectomy as well 
as TM who have undergone supracervical hysterectomy21. TM who have undergone total 
hysterectomy should not be included unless history of previous high-grade CIN18.  In those 
countries where cervical cancer screening for women in targeted age-groups is free of charge this 
should also be the case for TMs. 
While studies in ciswomen show that routine HPV-vaccination in public health programmes for 
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TM below the age of 25. As in cisgender woman, HPV-vaccination above the age of 25 is 
debatable28.
Health surveillance system should routinely collect transgender status information4. A paper by 
Gatos suggests a “two-question” approach, asking current gender identity and gender assigned 
at birth, separately. Specific guidelines need to be developed based on informed arguments23 as 
data on gender is sensitive and issues around data security and access complex and challenging.  
Other gender-related health conditions such as breast, neo-vagina and prostate cancer screening 
in transgender women also need to be addressed. Future research should focus on documenting 
the risks of high risk HPV and CIN in TM.
Conclusion
A significant proportion of TM retain their cervix and are at risk of cervical cancer due to an equal 
or possibly higher risk of acquiring HPV as well as personal and structural barriers to access 
cervical screening, this resulting in a lower uptake. Organised cancer screening programs have to 
include the needs of this population in general, including the benefits of HPV NAAT testing on 
self-samples in particular. Up to the age of 25, TM could be offered HPV vaccination if not 
already vaccinated. As in cisgender woman, HPV-vaccination above the age of 25 is debatable. 
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Lack of provider knowledge 
Identification of target population in organized 
programs if based on legal/registered gender 
identity
Lack of insurance coverage for procedures affecting 
anatomy not typically associated with an individual’s 
legally recognized gender 
Stigma and discrimination by healthcare providers 
and insurance providers, leading to postponement 
of care16
Overall lack of HPV and cancer research that 
includes transgender men and women as unique 
and disaggregated populations22 
Female-only waiting rooms 
Woman-centered and heteronormative patient 
education materials
Language from providers during the screening 
exam16 








Distrust of healthcare delivery systems due to a 
history of maltreatment
High prevalence of past sexual or emotional 
trauma16
Discomfort or distress caused by genital 
examination3,16,19,24 
Lack of knowledge that the cervix may be retained 
after some approaches to hysterectomy16
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